Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213732 | 1.00 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2GAARAB9A | |
| SCHEMBL10102972 | 0.84 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10102968 | 0.82 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13043754 | 0.82 | MAPT (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12975393 | 0.80 | — | — | |
| SCHEMBL17540104 | 0.78 | — | — | |
| SCHEMBL13267564 | 0.78 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12137048 | 0.75 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14191916 | 0.71 | MAPT (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14191919 | 0.71 | MAPT (0.38) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7157475-B2 | Diamide invertebrate pest control agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-4710320-A | REACTING 1-AMINO-2-HALOGENO-4-HYDROXYANTHRAQUINONES WITH PHENOLS IN A SULFOLANE SOLVENT WITH AN ACID BINDING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ALDH1A1 2335/4885SMN1; SMN2 3808/4885GAA 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.